文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

结核分枝杆菌环丝氨酸耐药相关新突变鉴定

Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

研究用含不同浓度d-环丝氨酸的7H11琼脂平板对结核分枝杆菌H37Rv进行体外耐药突变体筛选,分离18株耐药突变体并做全基因组测序。共鉴定16个基因突变与d-环丝氨酸耐药相关,仅alr基因突变见于已知耐药相关基因,另发现13个新基因单独突变相关,提示耐药机制涉及脂质代谢、甲基转移酶、应激反应和转运系统等多功能基因。

要点

  • 体外筛选18株d-环丝氨酸耐药结核分枝杆菌突变体并完成全基因组测序。
  • 鉴定16个耐药相关基因突变,仅alr为已知耐药相关基因。
  • 发现13个新基因单独突变与d-环丝氨酸耐药相关,机制较既往认知更复杂。

核心结论

  • d-环丝氨酸耐药机制比既往认知更复杂,涉及多个不同细胞功能基因的突变。

研究设计与样本

  • 在含不同浓度d-环丝氨酸的7H11琼脂平板上对结核分枝杆菌H37Rv进行体外耐药突变体筛选。
  • 共分离18株d-环丝氨酸耐药突变体并进行了全基因组测序。
  • 所鉴定耐药相关突变经PCR和Sanger测序确认。

主要发现

  • 共鉴定16个基因突变与d-环丝氨酸耐药相关。
  • 仅在alr(rv3423c)基因发现突变,未在ddl、cycA或ald等已知耐药相关基因发现突变。
  • 发现13个新基因单独突变与耐药相关:rv0059、betP(rv0917)、rv0221、rv1403c、rv1683、rv1726、gabD2(rv1731)、rv2749、sugI(rv3331)、hisC2(rv3772)、rv3345c与rv1435c的5'基因间区、rv0759c的3'区域。
  • 耐药相关基因参与脂质代谢、甲基转移酶、应激反应和转运系统等不同细胞功能。

临床怎么用

  • 为d-环丝氨酸耐药的分子检测开发提供候选基因靶点,但需在临床菌株中验证。
  • 提示d-环丝氨酸耐药机制复杂,评估耐药时不宜仅检测ddl、cycA或ald等已知基因。

局限性

  • 研究基于体外筛选的耐药突变体,需在临床菌株中验证这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: d-Cycloserine is an important second-line drug used to treat MDR- and XDR-TB. However, the mechanisms of resistance to d-cycloserine are not well understood. Here we investigated the molecular basis of d-cycloserine resistance using in vitro-isolated resistant mutants. METHODS: Mycobacterium tuberculosis H37Rv was subjected to mutant selection on 7H11 agar plates containing varying concentrations of d-cycloserine. A total of 18 d-cycloserine-resistant mutants were isolated and subjected to WGS. The identified mutations associated with d-cycloserine resistance were confirmed by PCR and Sanger sequencing. RESULTS: We identified mutations in 16 genes that are associated with d-cycloserine resistance. Interestingly, we found mutations only in alr (rv3423c) encoding alanine racemase, but not in other known d-cycloserine resistance-associated genes such as ddl, cycA or ald. Instead, we identified 13 new genes [rv0059, betP (rv0917), rv0221, rv1403c, rv1683, rv1726, gabD2 (rv1731), rv2749, sugI (rv3331), hisC2 (rv3772), the 5' intergenic region of rv3345c and rv1435c, and the 3' region of rv0759c] that had solo mutations associated with d-cycloserine resistance. Our findings indicate that the mechanisms of d-cycloserine resistance are more complex than previously thought and involve genes participating in different cellular functions such as lipid metabolism, methyltransferase, the stress response and transport systems. CONCLUSIONS: New mutations in diverse genes associated with d-cycloserine resistance have been identified that shed new light on the mechanisms of action and resistance of d-cycloserine. Future studies are needed to verify these findings in clinical strains so that molecular detection of d-cycloserine resistance for improved treatment of MDR-TB can be developed.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chen J, Zhang S, Cui P, et al. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017. PMID: 28961957. doi:10.1093/jac/dkx316

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。